Trial Profile
A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jul 2020
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis
- Focus Therapeutic Use
- Acronyms CIMAX
- Sponsors UCB
- 25 Jun 2020 Primary endpoint (Change from Baseline to Week 52 in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in the overall axial spondyloarthritis (axSpA) population, and the ankylosing spondylitis (AS) and nonradiographic axSpA (nr-axSpA) subpopulations) has been met.
- 25 Jun 2020 Results published in the Rheumatology
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism